November 29, 2016 - By Clifton Ray · 0 Comments
The stock of Cempra Incorporated (NASDAQ:CEMP) registered an increase of 10.21% in short interest. CEMP’s total short interest was 9.85 million shares in November as published by FINRA. Its up 10.21% from 8.94M shares, reported previously. With 1.49 million shares average volume, it will take short sellers 7 days to cover their CEMP’s short positions. The short interest to Cempra Incorporated’s float is 20.14%. The stock closed at $6.45 during the last session. It is down 64.48% since April 26, 2016 and is downtrending. It has underperformed by 69.74% the S&P500.
Cempra, Inc. is a clinical-stage pharmaceutical company. The company has a market cap of $330.18 million. The Firm is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. It currently has negative earnings. The Company’s lead product, solithromycin , is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications.
Insitutional Activity: The institutional sentiment decreased to 1.32 in Q2 2016. Its down 0.95, from 2.27 in 2016Q1. The ratio fall, as 10 funds sold all Cempra Inc shares owned while 23 reduced positions. 14 funds bought stakes while 61 increased positions. They now own 39.80 million shares or 3.16% more from 38.58 million shares in 2016Q1.
Amer Century Inc holds 0% or 56,412 shares in its portfolio. New York State Common Retirement Fund has invested 0% of its portfolio in Cempra Inc (NASDAQ:CEMP). Automobile Association reported 120,700 shares or 0.01% of all its holdings. National Bank & Trust Of Montreal Can, a Ontario – Canada-based fund reported 39,250 shares. The Denmark-based Cam Gp A S has invested 0.23% in Cempra Inc (NASDAQ:CEMP). Harvey Capital Inc holds 109,950 shares or 0.91% of its portfolio. Bb Biotech Ag holds 1.33% of its portfolio in Cempra Inc (NASDAQ:CEMP) for 2.04 million shares. Citigroup Incorporated last reported 0% of its portfolio in the stock. Pennsylvania last reported 70,158 shares in the company. Teacher Retirement Systems Of Texas, a Texas-based fund reported 5,370 shares. D E Shaw And has invested 0% of its portfolio in Cempra Inc (NASDAQ:CEMP). Bnp Paribas Arbitrage last reported 0% of its portfolio in the stock. Timessquare Capital Lc has 0.22% invested in the company for 2.05M shares. Knoll Lp has 180,800 shares for 0.97% of their US portfolio. Ubs Asset Management Americas last reported 17,700 shares in the company.
Out of 13 analysts covering Cempra (NASDAQ:CEMP), 3 rate it a “Buy”, 2 “Sell”, while 8 “Hold”. This means 23% are positive. Cempra has been the topic of 24 analyst reports since July 30, 2015 according to StockzIntelligence Inc. Jefferies maintained the stock with “Buy” rating in Tuesday, August 2 report. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, October 23. The stock has “Buy” rating given by TH Capital on Monday, October 19. Stifel Nicolaus maintained Cempra Inc (NASDAQ:CEMP) rating on Friday, June 24. Stifel Nicolaus has “Buy” rating and $47 price target. As per Sunday, November 13, the company rating was downgraded by Needham. The stock has “Outperform” rating given by Raymond James on Tuesday, September 13. Gabelli downgraded Cempra Inc (NASDAQ:CEMP) on Monday, November 7 to “Hold” rating. The stock of Cempra Inc (NASDAQ:CEMP) earned “Buy” rating by Janney Capital on Friday, December 11. Robert W. Baird downgraded it to “Underperform” rating and $6 target price in Wednesday, November 2 report. Raymond James downgraded Cempra Inc (NASDAQ:CEMP) on Wednesday, November 2 to “Market Perform” rating.
Cempra, Inc., incorporated on May 16, 2008, is a clinical-stage pharmaceutical company. The Firm is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. The Firm also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).
More notable recent Cempra Inc (NASDAQ:CEMP) news were published by: Fool.com which released: “Why Cempra Inc. Got Crushed Again” on November 02, 2016, also Fool.com with their article: “Why Cempra Inc Fell Over the Last 2 Days” published on November 08, 2016, Seekingalpha.com published: “Cempra Is Dead, Long Live Cempra!” on November 17, 2016. More interesting news about Cempra Inc (NASDAQ:CEMP) were released by: Prnewswire.com and their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” published on November 03, 2016 as well as Seekingalpha.com‘s news article titled: “Cempra: Retail Investors Beware” with publication date: November 11, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray